In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Omega Therapeutics (OMGA – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $3.68.
According to TipRanks, Tenthoff is a 4-star analyst with an average return of 8.4% and a 40.76% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and Syros Pharmaceuticals.
Currently, the analyst consensus on Omega Therapeutics is a Strong Buy with an average price target of $11.25.
See today’s best-performing stocks on TipRanks >>
Based on Omega Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $831 thousand and a GAAP net loss of $22.25 million. In comparison, last year the company earned a revenue of $595 thousand and had a GAAP net loss of $25.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omega Therapeutics (OMGA) Company Description:
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease.
Read More on OMGA:
- Largest borrow rate increases among liquid names
- Omega collaboration with Novo Nordisk ‘validation’ of OEG platform, says Wedbush
- Omega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo Nordisk
- Novo Nordisk enters research pacts with Omega Therapeutics, Cellarity
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
